Back to discover
Disease

Measles

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHMeasles
3
Publications
11
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2028.
  • 3 industry developments reported.
Upcoming Milestones
Clinical Milestones2View
Results expected 1
Recently completed 1
Industry & Market3View
Activity timeline5

Clinical trials

9 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
11
All trials
2
Active
9
Late-stage
6
Completed
Late-stage studies

A Phase 3a, Observer Blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Combined Measles, Mumps, Rubella, and Varicella Vaccine Compared With Intramuscular Administration of ProQuad When Administered as a Second Dose to Healthy Children Aged 15 Months to 6 Years of Age

Phase 3 · Recruiting · GlaxoSmithKline

Specific and Non-specific Effects of Measles and BCG Vaccines for Mother and Child

Phase 4 · Recruiting · Bandim Health Project

A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of SIBP's MMR Vaccine Compared to GSK MMR Vaccine in Children, 9-11 Months of Age

Phase 3 · Completed · Shanghai Institute Of Biological Products

A Phase Ⅳ, Randomized, Controlled, Open-label, Immunogenicity Study of Vero Cell-derived Inactivated Japanese Encephalitis Vaccine (JEV-I) Co-administered With Measles-Mumps-Rubella Vaccine (MMR)

Phase 4 · Completed · Liaoning Chengda Biotechnology CO., LTD

A Phase II / III, Clinical Trial to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella, Produced by Bio-Manguinhos / Fiocruz in 11-month-old Infants.

Phase 2/3 · Completed · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children

Phase 4 · Completed · Bandim Health Project
Recently completed

A Phase Ⅳ, Randomized, Controlled, Open-label, Immunogenicity Study of Vero Cell-derived Inactivated Japanese Encephalitis Vaccine (JEV-I) Co-administered With Measles-Mumps-Rubella Vaccine (MMR)

Phase 4 · Completed · Liaoning Chengda Biotechnology CO., LTD

A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of SIBP's MMR Vaccine Compared to GSK MMR Vaccine in Children, 9-11 Months of Age

Phase 3 · Completed · Shanghai Institute Of Biological Products

A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children

Phase 4 · Completed · Bandim Health Project

A Phase II / III, Clinical Trial to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella, Produced by Bio-Manguinhos / Fiocruz in 11-month-old Infants.

Phase 2/3 · Completed · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

Phase 2/3 · Completed · PT Bio Farma

Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine

Phase 4 · Completed · Assistance Publique - Hôpitaux de Paris

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20072024
Major themes7
  • Disease Outbreaks2
  • Communicable Diseases1
  • Family Characteristics1
  • Immune Tolerance1
  • Immunologic Memory1
  • Measles1
  • Models, Theoretical1
Leading journals3
  • PloS one1
  • Science (New York, N.Y.)1
  • Scientific reports1
Leading researchers8
  • Chen YH1
  • Choy DF1
  • de Swart RL1
  • de Vries RD1
  • Elledge SJ1
  • Fraser C1
  • Griffin DE1
  • Knip M1
Affiliations (unnormalised)6
  • Barbara Davis Center for Diabetes1
  • Brigham and Women's Hospital1
  • Children's Hospital1
  • Harvard Medical School1
  • Johns Hopkins Bloomberg School of Public Health1
  • Johns Hopkins University School of Medicine1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.

Identifiers
MeSHMeasles
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.